Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention.

[1]  P. Serruys,et al.  Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials , 2019, The Lancet.

[2]  G. Stone,et al.  Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: Meta-Analysis of Randomized Trials , 2018, Circulation.

[3]  R. Virmani,et al.  Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans , 2017, Journal of the American Heart Association.

[4]  Bernard Chevalier,et al.  Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials , 2017, Circulation.

[5]  P. Serruys,et al.  Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials. , 2017, Journal of the American College of Cardiology.

[6]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[7]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  G. Stone,et al.  Intravascular ultrasound–guided vs angiography‐guided drug‐eluting stent implantation in complex coronary lesions: Meta‐analysis of randomized trials , 2017, American heart journal.

[9]  J. Jeppesen,et al.  10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. , 2017, Journal of the American College of Cardiology.

[10]  D. Moliterno,et al.  More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents: Related Versus Unrelated Events. , 2017, Journal of the American College of Cardiology.

[11]  F. Eberli,et al.  Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. , 2016, European heart journal.

[12]  C. Toma,et al.  Failure Mechanisms and Neoatherosclerosis Patterns in Very Late Drug-Eluting and Bare-Metal Stent Thrombosis , 2016, Circulation. Cardiovascular interventions.

[13]  P. Serruys,et al.  Bioresorbable Vascular Scaffolds for Coronary Revascularization. , 2016, Circulation.

[14]  G. Stone,et al.  Very Late Thrombosis After Bioresorbable Scaffolds: Cause for Concern? , 2015, Journal of the American College of Cardiology.

[15]  C. V. van Mieghem,et al.  Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). , 2015, JACC. Cardiovascular interventions.

[16]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[17]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[18]  O. Panagiotou.  Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison Edited by Giuseppe Biondi-Zoccai , 2015 .

[19]  L. Mauri,et al.  Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. , 2014, European heart journal.

[20]  H. Bøtker,et al.  Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial , 2014, The Lancet.

[21]  P. Serruys,et al.  Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials , 2013, The Lancet.

[22]  M. Leon,et al.  Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. , 2013, JACC. Cardiovascular interventions.

[23]  苅尾 七臣,et al.  ガイドライン解説 AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease : 2011 update , 2012 .

[24]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[25]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[26]  G. Stone,et al.  Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. , 2011, JACC. Cardiovascular interventions.

[27]  Yoshihisa Nakagawa,et al.  Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation , 2010, Circulation. Cardiovascular interventions.

[28]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[29]  D. Baim,et al.  Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.

[30]  D. Baim,et al.  Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. , 1996, Journal of the American College of Cardiology.